Trial Profile
A phase 1 trial of extended MLN8054 dosing in patients with advanced malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2013
Price :
$35
*
At a glance
- Drugs MLN 8054 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 22 Apr 2008 New trial record.